Marksans Pharma Sustainability Profile
Marksans Pharma Limited, headquartered in India, is a prominent player in the global pharmaceutical industry, specialising in the development and manufacturing of generic and over-the-counter (OTC) products. Founded in 2001, the company has established a strong presence in key markets, including North America, Europe, and Asia, with a commitment to quality and innovation. With a diverse portfolio that includes formulations across various therapeutic areas, Marksans Pharma stands out for its robust research and development capabilities. The company is known for its unique approach to product development, ensuring compliance with international regulatory standards. Marksans has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its position as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Marksans Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Marksans Pharma's score of 10 is lower than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Marksans Pharma's reported carbon emissions
In 2024, Marksans Pharma reported total Scope 1 emissions of approximately 23,130,250 kg CO2e. This figure represents a slight increase from the previous year, 2023, when the company recorded about 22,110,220 kg CO2e in Scope 1 emissions. The emissions intensity for Scope 1 and Scope 2 combined was reported at 0.00271077 per rupee of turnover in 2024, compared to 0.00337455 in 2023, indicating a reduction in emissions intensity relative to revenue. Marksans Pharma has not disclosed any Scope 2 or Scope 3 emissions data, nor have they set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi). The company has not made any formal climate pledges or commitments to reduce emissions at this time. As a pharmaceutical company headquartered in India, Marksans Pharma's emissions data is self-reported and does not cascade from any parent organisation. The company continues to monitor its carbon footprint and emissions intensity as part of its operational strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 22,110,220 | 00,000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
How Carbon Intensive is Marksans Pharma's Industry?
How Carbon Intensive is Marksans Pharma's Location?
Marksans Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Marksans Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
